Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Severe Combined Immunodeficiency 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 56Etoposide 40Filgrastim 37Carboplatin 34Vincristine 30Doxorubicin 30Melphalan 27Topotecan 25Isotretinoin 24Peripheral Blood Stem Cell Transplantation 23Granulocyte Colony-Stimulating Factor 22Cisplatin 21Irinotecan 20sargramostim 18Temozolomide 17humanized 3F8 anti-GD2 monoclonal antibody 15Radiotherapy 153-Iodobenzylguanidine 13Granulocyte-Macrophage Colony-Stimulating Factor 11Busulfan 11dinutuximab 10Interleukin-2 9aldesleukin 8Thiotepa 8Ifosfamide 8etoposide phosphate 7Mesna 7Vorinostat 6Stem Cell Transplantation 6Polymerase Chain Reaction 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroblastoma × Prospective Studies × Clear all
NCT00695279 2024-10-30

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

St. Jude Children's Research Hospital

Completed
41 enrolled
CNSOther hematologic neoplasm

Mucopolysaccharidosis I, Neoplasms, Neuroblastoma, Severe Combined Immunodeficiency, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡